260 related articles for article (PubMed ID: 32636319)
1. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Kelley RK; Meyer T; Rimassa L; Merle P; Park JW; Yau T; Chan SL; Blanc JF; Tam VC; Tran A; Dadduzio V; Markby DW; Kaldate R; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Clin Cancer Res; 2020 Sep; 26(18):4795-4804. PubMed ID: 32636319
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
Kelley RK; Miksad R; Cicin I; Chen Y; Klümpen HJ; Kim S; Lin ZZ; Youkstetter J; Hazra S; Sen S; Cheng AL; El-Khoueiry AB; Meyer T; Abou-Alfa GK
Br J Cancer; 2022 Mar; 126(4):569-575. PubMed ID: 34621044
[TBL] [Abstract][Full Text] [Related]
7. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK; Ryoo BY; Merle P; Park JW; Bolondi L; Chan SL; Lim HY; Baron AD; Parnis F; Knox J; Cattan S; Yau T; Lougheed JC; Milwee S; El-Khoueiry AB; Cheng AL; Meyer T; Abou-Alfa GK
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847838
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Nguyen L; Chapel S; Tran BD; Lacy S
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):577-589. PubMed ID: 31637577
[TBL] [Abstract][Full Text] [Related]
9. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
14. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract][Full Text] [Related]
17. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
El-Khoueiry AB; Meyer T; Cheng AL; Rimassa L; Sen S; Milwee S; Kelley RK; Abou-Alfa GK
BMC Cancer; 2022 Apr; 22(1):377. PubMed ID: 35397508
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]